{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:55Z","timestamp":1788841375376,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ekir.2020.12.035","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T17:35:10Z","timestamp":1610645710000},"page":"881-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Rituximab in Membranous Nephropathy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5964-0307","authenticated-orcid":false,"given":"Philipp","family":"Gauckler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Crnogorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Delbarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kresimir","family":"Galesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn W.F.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir Singh","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth J.","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Segelmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zonozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Crnogorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Delbarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kresimir","family":"Galesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn W.F.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir Singh","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth J.","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Segelmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zonozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.12.035_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2215\/CJN.09000819","article-title":"Screening for cancer in patients with glomerular diseases","volume":"15","author":"Plaisier","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib7","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfg616","article-title":"Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy","volume":"19","author":"Ohtani","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.035_bib11","doi-asserted-by":"crossref","unstructured":"Caza T, Hassen S, Dvanajscak Z, et\u00a0al. NELL1 is a target antigen in malignancy-associated membranous nephropathy [e-pub ahead of print]. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2020.07.039, Accessed March 12, 2021.","DOI":"10.1016\/j.kint.2020.07.039"},{"key":"10.1016\/j.ekir.2020.12.035_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/Exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2020.12.035_bib16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2215\/CJN.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","article-title":"Primary glomerulonephritides","volume":"387","author":"Floege","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2020.12.035_bib22","article-title":"KDIGO Clinical Practice Guideline on Glomerular Diseases","year":"2020","journal-title":"Public Review Draft (June. 2020)"},{"key":"10.1016\/j.ekir.2020.12.035_bib23","doi-asserted-by":"crossref","unstructured":"Ponticelli C, Patrizia P, Del Vecchio L, Locatelli F. The evolution of the therapeutic approach to membranous nephropathy [e-pub ahead of print]. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa014, Accessed March 12, 2021.","DOI":"10.1093\/ndt\/gfaa014"},{"key":"10.1016\/j.ekir.2020.12.035_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/kisup.2012.20","article-title":"Chapter 7: Idiopathic membranous nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2020.12.035_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2020.12.035_bib26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2020.12.035_bib27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000437287","article-title":"Management of membranous nephropathy in Western countries","volume":"1","author":"Alfaadhel","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2020.12.035_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib30","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt A-Evd, et\u00a0al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [e-pub ahead of print]. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014, Accessed March 12, 2021.","DOI":"10.1016\/j.kint.2020.10.014"},{"key":"10.1016\/j.ekir.2020.12.035_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.12.035_bib34","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2020.12.035_bib35","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study","volume":"23","author":"Senthil Nayagam","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.035_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A\u00a0randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.12.035_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic adrenocorticotrophic hormone in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","author":"van de Logt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2020.12.035_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ckj\/sfw045","article-title":"Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis","volume":"9","author":"Kittanamongkolchai","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2020.12.035_bib39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/L19-0520","article-title":"Older drugs with limited trial evidence: are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel","volume":"171","author":"Duarte-Garcia","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib40","first-page":"427","article-title":"Treatment of membranous nephropathy in patients with renal insufficiency: what regimen to choose?","volume":"26","author":"Ponticelli","year":"2013","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib41","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib42","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.01920218","article-title":"Complications of immunosuppression in glomerular disease","volume":"13","author":"Jefferson","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.ekir.2020.12.035_bib44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2020.12.035_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib46","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.035_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","article-title":"Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab","volume":"1","author":"Waldman","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2020.12.035_bib48","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJMc1910393","article-title":"Rituximab or cyclosporine for membranous nephropathy","volume":"381","author":"Ponticelli","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib49","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJMc1910393","article-title":"Rituximab or cyclosporine for membranous nephropathy","volume":"381","author":"Waldman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ckj\/sfz127","article-title":"Treatment of idiopathic membranous nephropathy in adults: KDIGO. 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal","volume":"12","author":"Rojas-Rivera","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2020.12.035_bib51","article-title":"Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis","volume":"99","author":"Lu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2020.12.035_bib52","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib53","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000450659","article-title":"Rituximab in membranous nephropathy: not all studies are created equal","volume":"135","author":"Cravedi","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2020.12.035_bib55","doi-asserted-by":"crossref","unstructured":"Fenoglio R, Baldovino S, Sciascia S, et\u00a0al. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy [e-pub ahead of print]. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-020-00781-6, Accessed March 12, 2021.","DOI":"10.1007\/s40620-020-00781-6"},{"key":"10.1016\/j.ekir.2020.12.035_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2020.12.035_bib57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.035_bib58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.12.035_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ekir.2020.12.035_bib60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2020.12.035_bib61","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ekir.2020.12.035_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ekir.2020.12.035_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2020.12.035_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2020.12.035_bib65","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2020.12.035_bib66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2020.12.035_bib67","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib68","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2020.12.035_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000333068","article-title":"Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients","volume":"1","author":"Michel","year":"2011","journal-title":"Nephron Extra"},{"key":"10.1016\/j.ekir.2020.12.035_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","article-title":"Rituximab in patients with\u00a0phospholipase A2 receptor-associated membranous nephropathy and severe CKD","volume":"5","author":"Hanset","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2020.12.035_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib72","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2020.12.035_bib73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.12.035_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podesta","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ekir.2020.12.035_bib75","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.035_bib76","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"Dorner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2020.12.035_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12882-017-0459-z","article-title":"Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series","volume":"18","author":"Cortazar","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib78","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1046\/j.1523-1755.1998.00205.x","article-title":"Proteinuria selectivity index based upon alpha 2-macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases","volume":"54","author":"Tencer","year":"1998","journal-title":"Technical note. Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.035_bib80","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib81","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib82","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5414\/CN107912","article-title":"Rituximab for the\u00a0second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy","volume":"80","author":"Busch","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib83","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2020.12.035_bib84","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ckj\/sfw091","article-title":"Treatment with rituximab in idiopathic membranous nephropathy","volume":"9","author":"Fiorentino","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2020.12.035_bib85","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2020.12.035_bib86","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920318696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920318696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:35:55Z","timestamp":1762832155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024920318696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2468024920318696"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.12.035","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}